Join your peers and leading players in the worldwide biopharmaceutical industry to develop and foster collaboration among local and international companies and institutions.

Companies in China are increasingly being perceived as competitors and potential partners in novel biotherapeutics development. Local conglomerates are setting up biotherapeutic arms; multi-nationals are localizing research and development; innovative returnees are starting up new biotech ventures; and universities are spinning off novel ideas and training future generations in the protein sciences. All these are making China a futile fertile ground for the growth of novel biotherapeutics.

In its third year, PEGS China: Protein and Antibody Engineering & Development Summit returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.

This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.

April 5-6, 2016


Protein and Antibody Engineering


Analytical Characterization


April 6-7, 2016


Next Geneartion


Protein Aggregation & Stability




Keynote Speakers


Alain BeckAlain Beck, Ph.D., Senior Director, Antibody and ADC Physico-Chemistry, Centre d’Immunologie Pierre Fabre

Bradbury AndrewAndrew Bradbury, MBBS, Ph.D., Biosciences Division, Los Alamos National Laboratory

Roland KontermannRoland Kontermann, Ph.D., Professor, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart

Parren PaulPaul W.H.I. Parren, Ph.D., Senior Vice President & Scientific Director, Genmab

Weikang TaoWeikang Tao, Ph.D., Vice President & CEO, R&D Center, Jiangsu Henrui Medicine Co., Ltd.

Tessier PeterPeter M. Tessier, Ph.D., Richard Baruch M.D. Career Development, Associate Professor, Chemical & Biological Engineering, Rensselaer Polytechnic Institute

Ventura SalvadorSalvador Ventura, Ph.D., Professor, Biochemistry and Molecular Biology, Institute of Biotechnology and Biomedicine, University of Barcelona

Wu HerrenHerren Wu, Ph.D., Chief Technology Officer,


Hear from past attendees on their PEGS China experience:

“This conference is very successful, in my opinion, for it not only invites the top scientists in the field of therapeutic antibody, but also this event gives a chance for local companies to present their scientific achievements. I enjoyed the talks very much. Thank you again for the organization.”
- Liang (Leo) Qu, Ph.D., Roche Pharmaceutical Research and Early Development

“Congratulations on a successful PEGS China meeting. As a speaker and chair, I really enjoyed the conference and interactions with the attendees.”
- Kedan Lin, Genentech, Inc.

“Thanks again for such a great PEGS China in Shanghai - I really enjoyed meeting you again and attending this again very well organized conference! A job well done!”
- Jonas Schaefer, Ph.D., University of Zurich

“Thanks again for a great conference, I really enjoyed my PEGS-China experience.”
- Jonathan Lai, Ph.D., Albert Einstein College of Medicine

“I really enjoyed the conference and made some great contacts.”
- Stephen Mahler, Ph.D., University of Queensland

“I had a wonderful time and thought the conference was a success!”
- Thomas Pillow, Ph.D., Genentech, Inc.

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Register Early


Download 2016 Brochure
2016 ABA Brochure Icon


Premier Sponsor
Protein Simple

View All Sponsors >

View Media Partners >

Promote your company’s latest technology and/or solution at PEGS CHINA. A limited number of agenda presentations (as part of a sponsorship package), exhibit space, branding, and promotional opportunities are available.

Track 1

Protein & Antibody Engineering

Track 2

Analytical Characterization of Biotherapeutics

Track 3

Next-Generation Cancer Biotherapeutics

Track 4

Protein Aggregation & Stability


Clinical and Regulatory Strategies for Domestic and Global IND And BLA Filings